Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon
Tech Nation: My Creations Have Upgrade Panels
Chapter 177

2.4 Billion Hepatitis B Patients

1,254 words 4 min read 1 view 2mo ago Source ​
Skip to the end of the chapter
Prev
Next

It has been more than two months since Xingtu Gene Company launched its AIDS- specific drug 'EBT-002 Gene Therapy Agent'.

During these two months, thanks to the vast medical resources of Great Xia and the production capacity of 'EBT-002 gene therapy agent', the situation has been well managed.

Over the course of two months, more than 8.5 million people worldwide received the 'EBT-002 gene therapy' at Great Xia to treat their AIDS.

Of these 8.5 million people, the proportion of Great Xia people is actually not high.

Thanks to years of propaganda, Chinese people now avoid AIDS like the plague, and everyone is terrified of it.

Therefore, thanks to the effective publicity of Great Xia, before the launch of 'EBT-002 gene therapy drug', the number of AIDS patients in Great Xia was only around 1 million.

After two months, only one in ten AIDS patients remained in the Great Xia area.

Although the people of Great Xia to be poor, they are very good at saving money and can easily come up with a mere ten or twenty thousand yuan.

Under such circumstances, they are naturally willing to spend money to treat their AIDS, so as of now, there are fewer than 100,000 AIDS patients in the entire Great Xia.

Among the remaining 100,000 people are those who genuinely cannot afford treatment or are unwilling to spend the money on it.

Therefore, the current users of 'EBT-002 gene therapy drug' have actually been people overseas.

Among these foreign citizens, the number of AIDS in developed countries such as the American Empire, France, and island nations is actually not large, ranging from several hundred thousand to one million.

The countries with the highest proportion of AIDS patients are actually those that are not very developed or have poor management, such as South Africa, where the number of AIDS patients is as high as 7.2 million!

It can be said that of the 39 million people living with AIDS worldwide, this country accounts for 18% of the total, which is quite remarkable.

The second place is Mozambique, with 2.1 million people living with AIDS, and the third place is India, with 2 million people living with AIDS.

It can be said that in these countries with a large number of AIDS patients, either the people are relatively poor or the management is chaotic.

For people in these less developed countries, having to travel all the way to Great Xia to treat AIDS is simply too much of a hassle.

After all, going abroad has never been an easy thing, and it also costs a lot of money.

Many people are afraid of unfamiliar countries, worrying about security and the possibility of being bullied.

Given that the Broad Institute's 'Bode-001 AIDS treatment' is likely to be the first to hit the market, if Xingtu Technology's 'EBT-002 gene therapy' is delayed by a few months, it will be too late.

After all, they would certainly prefer to receive AIDS in their own country rather than travel abroad to Great Xia.

Moreover, the cost of treating AIDS in one's own country is definitely cheaper than going abroad for treatment.

If the 'EBT-002 gene therapy drug' really takes several months to reach the market, then what is it if it's already too late?

As for whether overseas markets will really delay the launch of 'EBT-002 gene therapy drug' by a few months?

In overseas countries where capital reigns supreme, the exchange of money for power is a common practice.

Overseas Medical Bureau can simply follow the standard review process for 'EBT-002 gene therapy drug' and still receive payment, so why not?

After all, it takes at least six months from application to market launch for a drug, and usually more than a year.

They reviewed the 'EBT-002 gene therapy drug' according to the normal procedures, allowing it to go through a six-month or even year-long process before it could be launched on the market. No one could say anything about that.

Under such circumstances, Lin Feng naturally had reason to believe that various overseas Medical Bureau would allow the 'EBT-002 gene therapy drug' to proceed according to standard procedures.

If they can go public in three months, that would be considered a light start; going public in a year is very likely.

But if it takes three months or a year for the gene therapy drug to be available on the market, how many AIDS patients will be left in the world by then, given its miraculous efficacy?

The remaining people are probably like the 100,000 people in Great Xia, either unwilling to spend money on treatment or simply unable to afford it.

Even if Xingtu Technology's 'EBT-002 gene therapy drug' had been approved and could have been listed overseas by then, it would have been too late.

This is naturally quite frustrating for Xingtu Technology, considering that there are 39 million AIDS patients worldwide, and Xingtu Gene Company only managed to capture a quarter of that market.

Not only could the remaining three-quarters of the cake not be eaten, but it was also blocked from the outside by despicable means, which naturally made people frustrated and want to vomit blood.

Therefore, if we don't want to face that situation, we must expedite the approval process for the clinical trial application and market launch of the 'EBT-002 gene therapy drug' overseas!

Thinking about this, Lin Feng put his hand on his chin and began to ponder.

They were thinking about how to expedite the approval process for the 'EBT-002 gene therapy drug' in various countries, instead of letting it drag on like this.

Firstly, the pressure from public opinion is not very effective, because Lin Feng does not have control over the discourse in overseas public opinion.

Although Lin Feng could influence the four major internet portals that cooperated with Xingtu Technology — Microsoft MSN Portal, Tencent Portal, and Sina Portal— to publish news articles that exerted public pressure through the Second-generation Douyin Recommendation Algorithm.

You can also exert public pressure through websites and apps such as Douyin, Bilibili, Tencent Video, YouTube, Facebook, Twitter, Weibo, and Tencent QQ, but the combined influence of these things is not significant.

Because the news landscape overseas is different from that in Great Xia, people overseas still prefer to read news from authoritative newspapers such as Reuters, The Global Daily the Times, The Globe and the London Daily News, the Sun.

After all, this is a tradition that has been accumulated over a hundred years, a matter of cultural habit, and they have also made electronic developments, issuing both paper and electronic versions at the same time, with a very high penetration rate.

Therefore, even if Xingtu Gene Company can exert public pressure and put pressure on the medical review authorities of those countries.

However, it's impossible to be certain how effective it will be, so Xingtu Gene Company lacks a definitive solution.

This decisive measure must be something that moves countries so much that they cannot refuse it, and even make them eager to resolve it.

After thinking it over, Lin Feng realized that the solution was to develop a new, highly effective drug.

The disease that this effective drug treats must be as dangerous as or comparable to AIDS, and the number of infected people must be much larger.

As for what this special medicine is?

Lin Feng had an idea in no time: Hepatitis B Special Medicine!

Although hepatitis B is not as highly valued in Great Xia as AIDS, and there are no advertisements for it in every toilet or medical facility, the situation is different.

However, the number of people who die from hepatitis B is not much less than that of AIDS, and the number of people infected with hepatitis B is six times more than that of AIDS patients!

In 2015, there were as many as 240 million hepatitis B patients worldwide, with 80 million of them becoming chronic hepatitis B patients.

End of Chapter
Prev
NovelSummaries
Next

Explore the wiki

Lin Feng
Xingtu Technology
Great Xia
American Empire
Bilibili

Comments

No comments yet.
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS